What's in Ahmad Zeeshan Jamil's pipeline?

Ahmad Zeeshan Jamil has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ahmad Zeeshan Jamil's portfolio?

Top competitors by shared drug class: Alvotech Swiss AG, Bayer, Ophthalmic Consultants of Boston, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ahmad-zeeshan-jamil.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Ahmad Zeeshan Jamil — Portfolio Competitive Intelligence Brief

Ahmad Zeeshan Jamil pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Aflibercept (Eylea)	Aflibercept (Eylea)	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)	Ophthalmology

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alvotech Swiss AG · 1 shared drug class
Bayer · 1 shared drug class
Ophthalmic Consultants of Boston · 1 shared drug class
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ahmad Zeeshan Jamil:

Cite this brief

Drug Landscape (2026). Ahmad Zeeshan Jamil — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ahmad-zeeshan-jamil. Accessed 2026-05-16.